J. Univ. Med. Dent. Coll., Vol.13(3), 430-435;2022 ISSN (Print) 2221-7827, ISSN (Online) 2310-5542 DOI: 10.37723/jumdc.v13i3.716 http://www.jumdc.com/

**Original Article** 

Open Access

# Role of prognostic factors in understanding disease severity in COVID-19 patients: Pakistan ordinance factories Hospital experience

Rifat Yasmin<sup>a</sup>, Huma Hussain<sup>b</sup>, SyedaTurab Fatima Abidi<sup>a</sup>, Syed Asim Ali Shah<sup>a</sup>, Lubna Ghazal<sup>c</sup>, Tazaeen Hina Kazmi<sup>a</sup>

<sup>a</sup>AssistantProfessor, Department of Medicine, POF Hospital, Wah Medical College (Affiliated with NUMS) Wah Cantt.

<sup>b</sup>AssistantProfessor, Department of EmergencyMedicine, POF Hospital, Wah Medical College (Afilliated with NUMS), WahCantt.

<sup>c</sup>AssistantProfessor, Department of Pathology, Wah Medical College (Affiliated with NUMS), WahCantt.

Corresponding author: rifatyasmin99@yahoo.com

## **ABSTRACT**

**BACKGROUND & OBJECTIVE:** Coronavirus disease (COVID-19) is an emerging public health challenge. Study was conducted to determine the association of prognostic factors with disease severity in COVID-19 patients at POF Hospital, Wah Cantt. We conducted a descriptive cross-sectional study at a department of Medicine, POF Hospital, Wah Medical College (affiliated with National University of Medical Sciences) Wah Cantt.

**METHODOLOGY:** We calculated sample size of 158 patients (WHO Calculator). The study duration was 6 months (November 2020-April 2021). The selection of COVID patients was done through non probability sampling (consecutive). Respiratory sample for all participating patients were collected (from throat or sputum). These samples were tested for SARS-CoV-2 using WHO standard. SPSS version 24 was utilized for data analysis purpose. Chi square test and independent t-test were applied. Logistic regression was applied.

**RESULTS:** Total data consist of 158 patients with COVID-19. Mean age of patients was52.3±3.26 years. Total leukocytes count (p=0.02), absolute neutrophil count (p=0.001), C reactive protein (p=0.001), NLR (p=0.03) were comparatively greater in patients with Severe COVID-19. While absolute lymphocyte were significantly lower in severe COVID-19 patients as compared to non-severe (p=0.03). Age [OR, 1.06;95% CI (1.027-1.114); p=0.001], diabetes mellitus[OR, 0.281;95% CI (0.100-0.788) p=0.016 and Hypertension [OR, 3.045;(1.044-8.878)95% CI p=0.04] are significant predictors of COVID-19 severity

**CONCLUSION:** Prognostic factors of COVID-19 increased the likelihood of disease progression. C reactive protein and ALC were significant predictors of COVID-19.

**KEYWORDS:** Coronavirus Disease, SARS-CoV-2, World Health Organization.


# INTRODUCTION

Coronavirus disease (COVID-19) is an emerging public health challenge. After the declaration of COVID-19 as a pandemic, 223 countries were reported to be affected with COVID-19 (178 million confirmed cases), and globally more than 3.8 million mortalities [1]. SARS-CoV-2 infection cases are found to be highest in United States followed by Brazil and India [2]. COVID-19 is 3rd leading cause of mortality in United States after cardiovascular disease and cancer in 2020<sup>[3]</sup>. Pakistan is also drastically affected by

COVID-19 with 1,274,017 confirmed cases, 28, 466 deaths, 1,234 critical cases, and 1,222,987 recovered patients (till Oct 2021). Moreover, 41,319,385 individuals are fully vaccinated in Pakistan [4].

Evidence exist that COVID-19 different variants spread to different countries with the passage of time. WHO reported that the Alpha, Beta, Gamma, and Delta variant spread to 170, 119, 71, and 85 countries, respectively. WHO reported a new variant of SARS-CoV-2 Omicron (B.1.1.529) that origin from South Africa (24 November 2021). Omicron is associated with several mutations, high potential of

Yasmin R, Hussain H, Abidi Syeda TF, Shah Syed AA, Ghazal A, et al. Role of prognostic factors in understanding disease severity in COVID-19 patients: Pakistan ordinance factories Hospital experience. Journal of University Medical & Dental College. 2022;13(3):430-435.



430

J Uni Med Dent Coll

transmissibility, and therapeutic resistance, and it could escape vaccine-induced immunity [5].

According to WHO, the case fatality rate for coronavirus disease is 2.2% (globally). This rate is affected by a number of prognostic factors, including the severity of illness, age, and underlying pre-existing conditions. The severity of COVID-19 is reported to be mild in 81% cases, severe in 14%, and critical in 5% of cases. However, fatality rate is 50% in critical cases <sup>[6]</sup>. A similar study reported gender, age, low oxygen saturation, high procalcitonin, comorbidities, low CD4 cell count, abnormal high lactate dehydrogenase level, and low albumin level as significant prognostic factors associated with COVID-19 patients<sup>[7]</sup>.

These prognostic factors vary in different countries according to disease severity. These factors help in the stratification of patients based on disease and mortality risk. This process of stratification helps clinicians in optimized management including maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19) and establishing resource utilization strategies for COVID-19 patients [8].

We could not found established prognostic factors for COVID-19 by scientific community. However, available prognostic factors did not have any predictive value and are nor robustly evaluated. So, they remained uncertain. Present study was planned to the determined association of prognostic factors with disease severity in COVID-19 patients at Pakistan Ordinance Factories Hospital, Wah Cantt.

# **METHODOLOGY**

Descriptive cross-sectional study was done at the Medicine department, POF Hospital, Wah Medical College (affiliated with National University of Medical Science) Wah Cantt. Theduration of study was months (November 2020-April 2021). A sample size of 158 COVID-19 patients was calculated with 95% confidence interval, moderate severity frequency 28%[9], 7% absolute precision using WHO calculator. We selected all patients of COVID-19 during the study through non-probability sampling (consecutive). All the enrolled patients of the study signed written consent for participation in study. Ethical approval was taken from the respective ethical approval committee of POF hospital (IRB No= ERC#POFH/ERC/10/20). Both gender, age  $\geq$ 18 years, and patients with COVID-19 diagnosis (using diagnostic criteria of New Coronavirus pneumonia prevention and control program) were included in study. Respiratory samples were collected from the throat or sputum. These samples are tested for SARS-CoV-2 using WHO standard (qualitative reverse transcriptase PCR). Positive results of COVID-19 were specified on the basis of a positive test from a given specimen. After admission, routine biochemical and hematological test were performed. Patients were monitored serially through chest X-rays and chest CT scan.

Severity of COVID-19 was defined on the basis of Shi et al<sup>[10]</sup> criteria as shown in table-I.

Table-I: Severity of COVID-19 Criteria.

| Mild disease     | On radiographic evaluation, findings will include mild symptoms and non-pneumonia.  |
|------------------|---|
| Moderate disease | On radiographic evaluation, fever, respiratory symptoms plus strong evidences of pneumonia  |
| Severe disease   | Severe dyspnea, respiratory frequency ( $\geq$ 30/min), lung infiltrates ( $>$ 50% of lung field)in the duration of 24 to 48 hours, Oxygen saturation ( $\leq$ 93%) and Pa02/FiO2 ratio of more than 300. |
| Critically ill   | Respiratory failure, multiple organ dysfunction/<br>failure, in need of mechanical ventilation, and<br>severe septic shock require ICU monitoring and<br>treatment.                                       |

Outcomes were measured in terms of mortality (death during data collection period), discharge or treated and pateints were still admitted in hospitals (during data collection). Data were analyzed using SPSS version 24. We measured frequencies and percentages for categorical and nominal data. Mean and Standard deviation were calculated as continuous variables. Chi-square test and independentt-test was applied. A logistic regression model was used in this study. Results with p-value < 0.05 were considered statistically significant in our study.

#### **RESULTS**

Total of 158 patients were included in the study. There were 101(63.9%) male and 57(36.1%) female. Mean age of patients was52.3±3.26 years. In our study, 62(39.2%) patients were diagnosed with diabetes mellitus, while 63(39.9%) patients were hypertensive.

Respiratory symptoms were observed in 12(7.6%) patients, however only 5(3.2%) were diagnosed with malignancies. No patient was pregnant in our data.

Table-I: Frequency distribution of severity of COVD-19 and outcome at 14 days of admission.

| Severity of COVID-19       | n(%)     |
|----------------------------|----------|
| Asymptomatic               | 2(1.3)   |
| Mild                       | 27(17.1) |
| Moderate                   | 56(35.4) |
| Severe                     | 25(15.8) |
| Critically ill             |          |
| Critical with Ards         | 39(24.7) |
| Critical with Sepsis       | 4(2.5)   |
| Critical with Septic shock | 5(3.2)   |
| Outcomes at 14 days        | -        |
| Treated/discharges         | 79(50)   |
| Still admitted             | 63(39.9) |
| Mortality                  | 16(10.1) |

Among all the patients, 16(10.2%) were active smokers, while 142(89.8%) were non-smokers. Severity and outcomes of study are shown in (Table-I). Mean days from onset to the presentation of disease were  $5.6\pm3.4$  days. Mean total leukocytes were  $8104.05\pm417.5$  cells/ $\mu$ L, mean absolute neutrophil count was  $6125.27\pm384.1$  cells/ $\mu$ L,

#### Yasmin R, Hussain H, Abidi Syeda TF.

mean absolute lymphocytes were 1782.01±884.1 cells/μL, mean C reactive protein 56.1±6.7 mg/L, mean neutrophil to lymphocyte ratio (NLR) was 7.5±2.4.

Total leukocytes count (p=0.02), absolute neutrophil count (p=0.001), C reactive protein (p=0.001), C NLR (p=0.03) were significantly high in patients with Severe COVID-19 as shown in table-II

The majority of patients in the age group 41-70 years had severe disease (14.6% vs 1.3%) as compared to patients in age group 18-40 years (p=0.001). Diabetes mellitus also showed a significant association with the severity of COVID-19 (p=0.001), as shown in table-III. Gender (p=0.574), Smoking (p=0.581), hypertension (p=0.068),

Ischemic heart disease (p=0.216), pregnancy (p=1.00), respiratory disease (p=0.764) and malignancy (p=0.261) showed insignificant association with severity of disease.

Critically ill conditions showed significant association with prognostic factors, including gender (p=0.021), age (p=0.001), diabetes mellitus (p=0.003), and malignancy (p=0.001) as shown in table-IV. While other prognostic factors smoking (p=1.00), hypertension (p=0.759), IHD (p=0.300), respiratory (p=0.761) are non-significant.

Table-V showsBinary logistic regression analysis. Age[OR, 1.06;95% CI (1.027-1.114);p=0.001], diabetes mellitus[OR, 0.281;95% CI (0.100-0.788) p=0.016 and Hypertension [OR, 3.045;(1.044-8.878)95% CI p=0.04].

Table-II: Laboratory parameters of COVID-19 patients.

| Laboratory Parameters                | Severity                                  |                                    |         |
|--------------------------------------|---|------------------------------------|---------|
|                                      | Non severe (asymptomatic, mild, moderate) | Severe (severe and critically ill) |         |
| Total leukocytes count (Cells/μL     | 7403.64±348.5                             | 8919.58±475.2                      | 0.02    |
| Absolute neutrophil count (cells/μL) | 5016.28±306.8                             | 7416.5±424.9                       | < 0.001 |
| Absolute lymphocyte count (cells/μL) | 2049.7±852.4                              | 1470.2±820.8                       | < 0.001 |
| C-reactive protein (mg/L)            | 28.1±3.7                                  | 88.7±7.9                           | < 0.001 |
| NLR                                  | 3.7±0.9                                   | 12.03±3.4                          | 0.03    |

Table-III: Association between prognostic factors and Severity of COVID-19.

| Prognostic |             | Severity     |           |           |           |                |         |  |  |
|------------|-------------|--------------|-----------|-----------|-----------|----------------|---------|--|--|
| factors    |             | Asymptomatic | Mild      | Moderate  | Severe    | Critically ill | p-value |  |  |
|            | Male        | 2(1.3%)      | 14(8.9%)  | 36(22.8%) | 16(10.1%) | 33(20.9%)      |         |  |  |
| Gender     | Female      | 0(0%)        | 13(8.2%)  | 20(12.7%) | 9(5.7%)   | 15(9.5%)       | 0.574   |  |  |
|            | 18-40 years | 2(1.3%)      | 16(10.1%) | 13(8.2%)  | 2(1.3%)   | 0(0%)          |         |  |  |
| Age        | 41-70 years | 0(0%)        | 11(7%)    | 43(27.2%) | 23(14.6%) | 48(30.4%)      | < 0.001 |  |  |
| Diabetes   | No          | 1(0.6%)      | 22(13.9%) | 41(25.9%) | 11(7%)    | 21(13.3%)      |         |  |  |
| Mellitus   | Yes         | 1(0.6%)      | 5(3.2%)   | 15(9.5%)  | 14(8.9%)  | 27(17.1%)      | < 0.001 |  |  |
|            | No          | 2(1.3%)      | 27(17.1%) | 55(34.8%) | 25(15.8%) | 44(27.8%)      |         |  |  |
| Malignancy | Yes         | 0(0%)        | 0(0%)     | 1(0.6%)   | 0(0%)     | 4(2.5%)        | 0.261   |  |  |

Table-IV: Association of prognostic indicators and critically ill patients.

| Prognostic factors |             | Critically ill |                          |                            |                                  |         |
|--------------------|-------------|----------------|--------------------------|----------------------------|----------------------------------|---------|
|                    |             | No critically  | Critically ill with ARDs | Critically ill with sepsis | Critically ill with septic shock | p-value |
|                    | Male        | 68(43.0%)      | 29(18.4%)                | 0(0%)                      | 4(2.5%)                          |         |
| Gender             | Female      | 42(26.6%)      | 10(6.3%)                 | 4(2.5%)                    | 1(0.6%)                          | 0.021   |
|                    | 18-40 years | 33(20.9%)      | 0(0%)                    | 0(0%)                      | 0(0%)                            |         |
| Age                | 41-70 years | 78(48.7%)      | 39(24.7%)                | 4(2.5%)                    | 5(3.2%)                          | < 0.001 |
| Diabetes           | No          | 75(47.5%)      | 20(12.7%)                | 0(0%)                      | 1(0.6%)                          | 0.003   |
| Mellitus           | Yes         | 35(22.2%)      | 19(12%)                  | 4(2.5%)                    | 4(2.5%)                          |         |
| Malignancy         | No          | 109(69.0%)     | 37(23.4%)                | 4(2.5%)                    | 3(1.9%)                          |         |
|                    | Yes         | 1(0.6%)        | 2(1.3%)                  | 0(0%)                      | 2(1.3%)                          | <0.001  |

432 J Uni Med Dent Coll

Table-V: Regression model for prognostic factors (Logistic regression model).

| Prognostic factors | Regression Model   |         |                    |                    |         |  |
|--------------------|--------------------|---------|--------------------|--------------------|---------|--|
|                    | OR (95% CI)        | p-value | Prognostic Factors | OR (95% CI)        | p-value |  |
| Gender             | 1.43(0.491-4.197)  | 0.509   | ANC                | 1.0(1.0-1.0)       | 0.293   |  |
| Age                | 1.069(1.027-1.114) | 0.001   | ALC                | 0.999(0.998-1.00)  | 0.016   |  |
| Diabetes mellitus  | 0.281(0.100-0.788) | 0.016   | CRP                | 1.019(1.007-1.030) | 0.001   |  |
| Hypertension       | 3.045(1.044-8.878) | 0.041   | NLR                | 1.005(0.987-1.023) | 0.589   |  |
| Respiratory        | 0.322(0.062-1.680) | 0.179   | LCR                | 1.00(0.999-1.001)  | 0.821   |  |
| IHD                | 7.35(0.197- 2.736) | 0.646   | TLC                | 1.00(1.00-1.00)    | 0.414   |  |
| Malignancy         | 0.268(0.20-3.611)  | 0.321   | -                  | -                  | -       |  |
| Smoking            | 0.399(0.082-1.933) | 0.254   | -                  | -                  | -       |  |
| Renal              | 0.385(0.069-2.139) | 0.276   | -                  | -                  | -       |  |

#### **DISCUSSION**

Prognostic factors guide physicians about the severity of disease and risk of mortality. COVID-19 risk factors stands alone or in combination with risk associated models play a significant role in the optimized process and resource utilization in future for patients care in COVID-19<sup>[11]</sup>.

In the present study, age, diabetes mellitus, hypertension, high CRP, and reduction in ALC are significant predictors of the Severity of COVID-19 (p<0.05). Kornumet al. reported that high mortality risk in type 2 diabetes mellitus is associated with pneumonia on admission in hospital, while in non-diabetic patients, its s associated with communityacquired pneumonia<sup>[12]</sup>. Yang et al. reported that SARS CoV-2 patients' mortality is associated with diabetes mellitus and ambient hyperglycemia as an independent risk factor [13]. Mechanism behind poor clinical outcomes of COVID-19 diabetic patients includes, T lymphocyte response reduction, immunity disorders, neutrophil function reduction, and antioxidant system depression [14]. Another similar study reported that diabetic patients diagnosed with COVID-19 are at greater risk of disease severity associated with inflammatory factors, organ damage, and hypercoagulability [15]. Guan et al. reported that diabetes mellitus is the most influenced factor in COVID-19 patients. They are at more risk of disease development and rapid clinical deterioration [16].

In the present study, age (p=0.04) is an important factor to get disease severity and poor prognosis. Li et al. reported that the high age group, high LDH level, high cytokine levels and hypertension are significant predictors of COVID-19 severity [17]. Another study reported that body temperature, peripheral oxygen saturation <92%, creatine kinase, male (sex) and high age group was more likely to develop severe COVID-19 (with the increasing number of prognostic factors)<sup>[18]</sup>.

In our study, Total leukocytes count (p=0.02), absolute neutrophil count (p=0.001), C reactive protein (p=0.001), NLR (p=0.03) were significantly high in patients with Severe COVID-19. A similar study reported that eosinophils and lymphocyte count was significantly lower in patients with

severe COVID-19 (p=0.002 and p=0.001) [19]. Evidence exist that T lymphocytes and B lymphocytes were significantly lower than in critically ill patients [20]. Similar studies reported that AST, ALT, GGT, AND LDH were elevated in severe COVID-19 patients [21]. A study reported that high white blood cells count, low blood platelet count, high blood D-dimer, high blood C-reactive protein, high blood neutrophil count, and high blood bilirubin are significant predictors of COVID-19 severity [22]. Proper knowledge and dissemination of information is very important in understanding the disease at variour levels [23-25].

**Strength:** It's a new study in developing and resource limited country like Pakistan.

**Limitation:**Results of our study are not generalizable to whole population affected with COVID-19 because our study was restricted to single center. Another limitation is that we didn't consider antiviral agents and corticosteroid usage as a variable in our data. We also did not considercytokines (proinflammatory) and early CD8+T (cell response) associated with COVID-19 severity. Selection bias was not controlled due to a limited number of patients.

#### **CONCLUSION**

Prognostic factors of COVID-19 increase the likelihood of disease progression. Disease severity of COVID-19 is associated with age, diabetes mellitus, hypertension, and other laboratory parameters. We need to assess and monitor closely prognostic factors that help in the development of important and immediate interventions regarding COVID-19 severity in the health sector.

ACKNOWLEDGEMENT: None.
CONFLICT OF INTEREST: None.
GRANT SUPPORT & FINANCIAL DISCLOSURE:
None.

# **REFERENCES:**

 Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020;109:102433. Doi:10.1016/j.jaut.2020.102433

- 2. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. Journal of Autoimmunity. 2020;109:102434. Doi: 10.1016/j.jaut.2020.102434
- 3. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. American Journal of respiratory and critical care medicine. 2020;201(11):1372-1379.Doi:10.1164/rccm.202003-0543OC
- Government of Pakistan. COVID-19 situation. 2021[Cited 2022 January 05]. Available from:https://covid.gov.pk/
- 5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020;8(4):420-422.Doi.10.1016/S2213-2600(20)30076-X
- 6. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. The lancet Gastroenterology & Hepatology. 2020;5(5):428-430. Doi: 10.1016/S2468-1253(20)30057-1
- 7. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Journal of the American Medical Association. 2020;323(13):1239-1242. Doi:10.1001/jama.2020.2648
- 8. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology. 2020;146(1):110-118. Doi:10.1016/j. jaci.2020.04.006
- 9. Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). Journal of Internal Medicine. 2020;288(1):128-138. Doi:10.1111/joim.13063
- **10.** Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Critical care. 2020;24(1):1-4. Doi:10.1186/s13054-020-2833-7
- **11.** Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clinical Microbiology and Infection. 2020;26(6):767-772.Doi:10.1016/j.cmi.2020.04.012
- **12.** Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes care. 2007;30(9):2251-2257. Doi:10.2337/dc06-2417

- **13.** Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Medicine. 2006;23(6):623-628.
- 14. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian journal of endocrinology and metabolism. 2012;16(Suppl1):S27-S36.Doi:10.4103/2230-8210.94253
- **15.** Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. Journal Citation Indicator insight. 2019;4(20): e131774.
- 16. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720. Doi: 10.1056/NEJMoa2002032
- **17.** Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Investigative Radiology. 2020.Doi: 10.1097/RLI.000000000000000672
- **18.** Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-1009. Doi:10.1136/gutjnl-2020-320926
- **19.** Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-Lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. Journal of Translational Medicine. 2020;18(1):206-208. Doi:10.1186/s12967-020-02374-0.
- **20.** Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.Doi:10.1016/j.ebiom.2020.102763
- 21. Izcovich A, Ragusa MA, Tortosa F, LavenaMarzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PloS one. 2020;15(11):e0241955.Doi:10.1371/journal.pone.0241955
- **22.** Waris A, Din M, Khalid A, Abbas Lail R, Shaheen A, Khan N, et al. Evaluation of hematological parameters as an indicator of disease severity in Covid-19 patients: Pakistan's experience. Journal of Clinical Laboratory Analysis. 2021;35(6):e23809. Doi:10.1002/jcla.23809
- 23. Tariq S, Tariq S, Baig M, Alam SS. Adequacy of preventive measures, awareness, and attitude regarding the COVID-19 pandemic among university pharmacy students. Pharmacy Education. 2020;20(2):283-289. Doi:10.46542/pe.2020.202.283289

434 J Uni Med Dent Coll

- 24. Rizwan M, Ahmad T, Qi X, Murad MA, Baig M, Sagga AK, et al. Social media use, psychological distress and knowledge, attitude, and practices regarding COVID-19 among a sample of Pakistani population: the role of gender. Frontiers in Medicine. 2021:1803. Doi:10.3389/fmed.2021.754121
- **25.** Baig M, Tariq S, Tariq S. COVID-19 pandemic upshots and where will it lead us?. Journal of University Medical & Dental College. 2022;13(2):iv-v. Doi: 10.37723/jumdc.v13i2.741

# Author's Contribution:

**Rifat Yasmin:** Conception, drafting, write-up and final approval, tool development

Huma Hussain: Data collection and analysis

SyedaTurab Fatima Abidi: Analysis and results write-up. Syed Asim Ali Shah: Conception, critical revision of data. Lubna Ghazal: Revision of manuscript and data interpretation.

**Tazaeen Hina Kazmi:** Final approval of the version to be published.

Submitted for publication: 03-01-2022 Accepted after revision: 02-08-2022